AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.07

+1.9%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$900.68M
EPS-1.7400
P/E Ratio-5.21
Earnings Date08/12/2026

spry

Common Stock

Last Annual Value

10.00K

3-Year CAGR

4%

5-Year CAGR

-46%

10-Year CAGR

%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Common Stock

SPRY · NASDAQ
CompanyCommon Stock
CAGR 3Y
CAGR 5Y
CAGR 10Y
10.00K
0.0%27.2%N/A 
1.42B
1.7%2.0%5.1%
SVRA logo
Savara Inc.
NASDAQ:SVRA
204.00K
13.4%12.0%44.9%
9.00K
8.7%5.2%16.2%
12.00K
N/A-30.1%N/A
1.00K
-53.6%0.0%N/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
30.00K
9.3%-82.6%N/A
5.00K
7.7%4.6%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
87.00K
33.0%61.2%9.5%
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.07, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.07